Teva wins broader nod for Copaxone; Tokai touts positive PhII for prostate cancer drug;

@FierceBiotech: IPO hopefuls look to extend biotech's window with $123M in fresh pitches. More | Follow @FierceBiotech

@JohnCFierce: Amgen extends PhIII sweep with more promising results for PCSK9 drug. Story | Follow @JohnCFierce

@DamianFierce: Novartis races to the FDA with its 'breakthrough' lung cancer drug. More | Follow @DamianFierce

@EmilyMFierce: Yesterday's issue of FierceBiotech Research featured microbiota and virus-free stem cells. Check it out here. | Follow @EmilyMFierce

> After enduring a European setback for laquinimod, Teva's ($TEVA) would-be successor to the multiple sclerosis treatment Copaxone, the Israeli drugmaker won FDA approval for a longer-acting formulation of the old multibillion-dollar drug. Article

> Cambridge, MA's Tokai Pharmaceuticals reported positive interim results from its Phase II study of TOK-001 for castration-resistant prostate cancer, charting promising reductions in prostate-specific androgen in 79% of patients. Release

> Patients taking Pfizer's ($PFE) Xalkori for ALK-positive lung cancer can safely endure up to three courses of targeted radiation therapy, according to a study, leading to improved two-year survival rates. More

Medical Device News

@FierceMedDev: Hydrogel with tiny capsules could control the release of drugs. More from FierceDrugDelivery | Follow @FierceMedDev

@MichaelGFierce: Nanodiamonds covered in silk promise smoother drug delivery. Story | Follow @MichaelGFierce

@EmilyWFierce: GenePeeks lets women get a closer look at potential donors' DNA, predict risk for disease in hypothetical child. Article | Follow @EmilyWFierce

@GalenMoore: Wait times for a doctor's appointment are longest in Boston, shortest in Dallas, survey says. Survey | Follow @GalenMoore

> Abbott slashes jobs at corporate headquarters. More

> Illumina's sales soar 24% with sights set on a big 2014. Story

> Medtronic's stent graft follows Gore's into aortic dissections with FDA approval. News

Pharma News

@FiercePharma: Our newest publication, FiercePharmaMarketing, is now live at fiercepharmamarketing.com. All marketing, all the time. | Follow @FiercePharma

@TracyStaton: FDA approval, check. Now Teva has to woo patients to new longer-acting. Story | Follow @TracyStaton

@EricPFierce: Lilly announced 1,000 job cuts in 2013. 2014 expected to be even bleaker. Report | Follow @EricPFierce

@CarlyHFierce: And here's the rundown from @TracyStaton on what the new pub has in store. Item | Follow @CarlyHFierce

> Novartis expects a generic of Diovan to finally arrive in April. Story

> Louisiana high court tosses $257M Risperdal verdict for lack of evidence. Report

> New data positions Astellas prostate cancer med Xtandi to grab market share from J&J's Zytiga. More

Drug Delivery News

> Hydrogel with tiny capsules could control the release of drugs. Story

> URI scientist collects $1.3M to blast tumors with nanoparticles. More

> Nanodiamonds covered in silk promise smoother drug delivery. Article

> Nanogold 'superstructures' are held together with DNA for cancer drug delivery. News

> Evoke Pharma's nasal spray outdoes oral generic for diabetes-related stomach disease. Piece

> Artificial pancreas news: U.K. researchers unveil device, Animas snags Canadian approval of closed-loop system. Item

Diagnostics News

> Fluidigm is acquiring DVS in a $208M single-cell technology buyout. Story

> MDxHealth teams up with Teva to distribute its prostate, brain cancer tests. Article

> Will the real $1,000 genome please stand up? Story

> Epic Sciences teams with LabCorp to push its cancer diagnostic. News

> Nanostring grabs $55M in a follow-on offering. Article

> DioGenix's multiple sclerosis test hits the mark in a study. Item

Pharma Marketing News

> J&J persuades LA Supreme Court to toss $257M Risperdal marketing verdict. Story

> FDA approval, check. Now Teva has to woo patients to new, longer-acting Copaxone. News

> J&J tops 2013 journal-ad ranks with millions in print support for Invokana, Xarelto. Article

> Vivus, Arena hope Aetna weight-management program boosts diet-drug sales. Piece

> Priligy maker Menarini puts rugby players on cinema screens in premature-ejaculation awareness push. Item

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.